Abivax initiates clinical trial (ABX464-005) to evaluate effect of ABX464 on HIV-reservoirs in HIV patients

* Initiates clinical trial (ABX464-005) to evaluate the effect of ABX464 on HIV-reservoirs in HIV patients

* Initial results are expected in Q3 2017 

Read the article here

Press contacts

Caroline Carmagnol 

abivax@alizerp.com

+ 33 6 64 18 99 59 or
+ 33 1 44 54 36 65

 Standard: +33 1 53 83 08 41

More articles in French

Click here